Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Department of Cancer Prevention, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Curr Oncol. 2023 Mar 13;30(3):3301-3314. doi: 10.3390/curroncol30030251.
The appropriate management strategies for BI-RADS category 4a lesions among handheld ultrasound (HHUS) remain a matter of debate. We aimed to explore the role of automated breast ultrasound (ABUS) or the second-look mammography (MAM) adjunct to ultrasound (US) of 4a masses to reduce unnecessary biopsies. Women aged 30 to 69 underwent HHUS and ABUS from 2016 to 2017 at five high-level hospitals in China, with those aged 40 or older also accepting MAM. Logistic regression analysis assessed image variables correlated with false-positive lesions in US category 4a. Unnecessary biopsies, invasive cancer (IC) yields, and diagnostic performance among different biopsy thresholds were compared. A total of 1946 women (44.9 ± 9.8 years) were eligible for analysis. The false-positive rate of category 4a in ABUS was almost 65.81% (77/117), which was similar to HHUS (67.55%; 127/188). Orientation, architectural distortion, and duct change were independent factors associated with the false-positive lesions in 4a of HHUS, whereas postmenopausal, calcification, and architectural distortion were significant features of ABUS (all < 0.05). For HHUS, both unnecessary biopsy rate and IC yields were significantly reduced when changing biopsy thresholds by adding MAM for US 4a in the total population (scenario #1:BI-RADS 3, 4, and 5; scenario #2: BI-RADS 4 and 5) compared with the current scenario (all < 0.05). Notably, scenario #1 reduced false-positive biopsies without affecting IC yields when compared to the current scenario for ABUS ( < 0.001; = 0.125). The higher unnecessary biopsy rate of category 4a by ABUS was similar to HHUS. However, the second-look MAM adjunct to ABUS has the potential to safely reduce false-positive biopsies compared with HHUS.
手持超声(HHUS)BI-RADS 4a 类病变的适当管理策略仍存在争议。我们旨在探讨自动乳腺超声(ABUS)或超声(US)辅助的第二眼乳腺 X 线摄影(MAM)在减少不必要的活检方面对 4a 类肿块的作用。2016 年至 2017 年,中国五家高水平医院的年龄在 30 至 69 岁的女性接受了 HHUS 和 ABUS 检查,年龄在 40 岁或以上的女性还接受了 MAM 检查。Logistic 回归分析评估了与 US 4a 类假阳性病变相关的图像变量。比较了不同活检阈值下不必要的活检、浸润性癌(IC)检出率和诊断性能。共有 1946 名女性(44.9±9.8 岁)符合分析条件。ABUS 中 4a 类的假阳性率几乎为 65.81%(77/117),与 HHUS(67.55%;127/188)相似。方位、结构扭曲和导管改变是 HHUS 4a 类假阳性病变的独立相关因素,而绝经后、钙化和结构扭曲是 ABUS 的显著特征(均 < 0.05)。对于 HHUS,当通过在总人群中添加 MAM 改变 US 4a 的活检阈值时,无论是不必要的活检率还是 IC 检出率均显著降低(方案#1:BI-RADS 3、4 和 5;方案#2:BI-RADS 4 和 5),与现行方案相比(均 < 0.05)。值得注意的是,与 ABUS 现行方案相比,方案#1 在不影响 IC 检出率的情况下减少了 4a 类假阳性活检( < 0.001; = 0.125)。ABUS 对 4a 类的较高不必要活检率与 HHUS 相似。然而,与 HHUS 相比,ABUS 辅助的第二眼 MAM 有潜力安全地减少不必要的假阳性活检。